Pharma Veterans

  WHO Prequalifies First Ever Malaria Treatment for Newborns and Infants – Asrar Qureshi’s Blog Post #1259 Dear Colleagues! This is Asrar Qureshi’s Blog Post #1259 for Pharma Veterans. Pharma Veterans Blogs are published by Asrar Qureshi on its dedicated site https://pharmaveterans.com. Please email to pharmaveterans2017@gmail.com  for publishing your contributions here. Preamble The WHO prequalified Coartem Baby in April 2026 as a malaria treatment designed for infants weighing 2–5 kg (4.4–11 lb). These sweet cherry-flavored, dissolvable tablets treat acute, uncomplicated malaria, addressing a gap in neonatal care. The drug has been developed by Novartis and Medicines for Malaria Venture and is designed for distribution in high-risk areas.  The drug contains artemether and lumefantrine. The combination is not new as such; it has been in use for children and adults for many years. However, the use in newborns and infants was not qualified and relevant dosage forms were no...

  Child Mortality Progress Slows Down – Asrar Qureshi’s Blog Post #1241 Dear Colleagues! This is Asrar Qureshi’s Blog Post #1241 for Pharma Veterans. Pharma Veterans Blogs are published by Asrar Qureshi on its dedicated site https://pharmaveterans.com. Please email to pharmaveterans2017@gmail.com  for publishing your contributions here. Credit: Eddie* Malika Credit: Thato Moiketsi Credit: Greta Hoffman Preamble This blogpost is based on UN reports. Link at the end. A Story of Progress, Now at Risk – 4.9 million Children Under Five Die in 2024 In a world that prides itself on scientific progress, technological breakthroughs, and economic growth, one statistic remains deeply unsettling: millions of children continue to die every year from causes we already know how to prevent. A recent global report highlights a sobering reality, approximately 4.9 million children under the age of five died in 2024, a figure that underscores both progress made and the dangerous slowdown now unde...